Rajesh Patel, MD
Internal Medicine · Lock Haven, PANPI 1013985936
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,068 of the $106,993 with a category attached, or 68.3%. 50 manufacturers reported payments, led by Novo Nordisk at 26.1% of the total. 2025 is the largest year on record at $28,578, 2.9 times the $9,921 reported in 2019. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 933 payments — averaging $114.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$28K
- AbbVie$24K
- Phathom Pharmaceuticals, Inc.$19K
- Lilly USA, LLC$16K
- Johnson & Johnson$8K
- Eli Lilly$3K
- plus $9K from 44 others
Across 85 payments — averaging $1712.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$51K
- Bayer$45K
- GSK$16K
- Novo Nordisk AS$15K
- Boehringer Ingelheim International GmbH$7K
- Amarin Pharma, Inc.$6K
- plus $5K from 1 others
What the payments were for
- Consulting fees$4,1404%
- Speaking & faculty fees$73,06868%
- Travel & lodging$12,79412%
- Food & beverage$16,79516%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,993 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $223,362 |
| XareltoRivaroxaban | 281 | $168,628 |
| EliquisApixaban | 254 | $123,147 |
| JardianceEmpagliflozin | 154 | $112,201 |
| RybelsusSemaglutide | 90 | $101,701 |
| MounjaroTirzepatide | 73 | $89,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $78,626 |
| KerendiaFinerenone | 54 | $40,512 |
| LinzessLinaclotide | 54 | $34,104 |
| TrulicityDulaglutide | 25 | $30,874 |
| OzempicSemaglutide | 17 | $23,608 |
| ZenpepLipase/Protease/Amylase | 13 | $18,202 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $17,019 |
| TradjentaLinagliptin | 16 | $14,365 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $13,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $473 | $223,36211 claims |
| Johnson & JohnsonXarelto, Invokana | $7,578 | $179,606295 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $493 | $140,534185 claims |
| Novo NordiskRybelsus, Ozempic | $27,950 | $125,309107 claims |
| PfizerEliquis | $795 | $123,147254 claims |
| Lilly USA, LLCMounjaro, Trulicity | $15,882 | $120,25898 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $473 | $94,898132 claims |
| BayerKerendia | $646 | $40,51254 claims |
| AbbVieLinzess | $24,377 | $34,10454 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $556 | $29,22939 claims |
| Aimmune Therapeutics, Inc.Zenpep | $284 | $18,20213 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $13,84127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Lock Haven
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.